A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer

References

• Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 2008; 14:8010-18; PMID:19088017; http://dx.doi.org/10.1158/1078-0432.CCR-08-1208
   PubMed Web of Science ®Google Scholar
• Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology 2008; 52:108-18; PMID:18171422; http://dx.doi.org/10.1111/j.1365-2559.2007.02889.x
   PubMed Web of Science ®Google Scholar
• Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 2009; 115:423-28; PMID:18543098; http://dx.doi.org/10.1007/s10549-008-0086-2
   PubMed Web of Science ®Google Scholar
• Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-52; PMID:10963602; http://dx.doi.org/10.1038/35021093
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010; 363:1938-48; PMID:21067385; http://dx.doi.org/10.1056/NEJMra1001389
   PubMed Web of Science ®Google Scholar
• Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer:clinical features and patterns of recurrence. Clin Cancer Res 2007; 13:4429-34; PMID:17671126; http://dx.doi.org/10.1158/1078-0432.CCR-06-3045
   PubMed Web of Science ®Google Scholar
• Kassam F, Enright K, Dent R, Dranitsaris G, Myers J, Flynn C, Fralick M, Kumar R, Clemons M. Survival outcomes for patients with metastatic triple-negative breast cancer:implications for clinical practice and trial design. Clin Breast Cancer 2009; 9:29-33; PMID:19299237; http://dx.doi.org/10.3816/CBC.2009.n.005
   PubMed Web of Science ®Google Scholar
• Andre F, Job B, Dessen P, Tordai A, Michiels S, Liedtke C, Richon C, Yan K, Wang B, Vassal G, et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 2009; 15:441-51; PMID:19147748; http://dx.doi.org/10.1158/1078-0432.CCR-08-1791
   PubMed Web of Science ®Google Scholar
• Bergamaschi A, Kim YH, Wang P, Sorlie T, Hernandez-Boussard T, Lonning PE, Tibshirani R, Borresen-Dale AL, Pollack JR. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 2006; 45:1033-40; PMID:16897746; http://dx.doi.org/10.1002/gcc.20366
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM, Bradley C. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364:205-14; http://dx.doi.org/10.1056/NEJMoa1011418
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy J, Schwartzberg LS, Danso MA, Rugo HS, Miller K, Yardley R, Al E. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 2011; 29:1007; http://dx.doi.org/10.1200/JCO.2009.27.8960
   PubMed Web of Science ®Google Scholar
• Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, et al. TBCRC 001:randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol 2012; 30:2615-23; PMID:22665533; http://dx.doi.org/10.1200/JCO.2010.34.5579
   PubMed Web of Science ®Google Scholar
• Baselga J, Gomez P, Greil R, Braga S, Climent MA, Wardley AM, Kaufman B, Stemmer SM, Pego A, Chan A, et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol 2013; 31:2586-92; PMID:23733761; http://dx.doi.org/10.1200/JCO.2012.46.2408
   PubMed Web of Science ®Google Scholar
• Isakoff SJ, Goss PE, Mayer EL, Traina TA, Carey LA, Krag K, Rugo HS. TBCRC009:A multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response. J Clin Oncol 2011; 29:1025; http://dx.doi.org/10.1200/JCO.2010.31.6679
   Web of Science ®Google Scholar
• ClinicalTrials.gov:Triple negative breast cancer trial (TNT).
   Google Scholar
• Staudacher L, Cottu PH, Dieras V, Vincent-Salomon A, Guilhaume MN, Escalup L, Dorval T, Beuzeboc P, Mignot L, Pierga JY. Platinum-based chemotherapy in metastatic triple-negative breast cancer:the Institut Curie experience. Ann Oncol 2011; 22:848-56; PMID:20924076; http://dx.doi.org/10.1093/annonc/mdq461
   PubMed Web of Science ®Google Scholar
• Fan Y, Xu BH, Yuan P, Ma F, Wang JY, Ding XY, Zhang P, Li Q, Cai RG. Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Ann Oncol 2013; 24:1219-25; PMID:23223332; http://dx.doi.org/10.1093/annonc/mds603
   PubMed Web of Science ®Google Scholar
• Bhattacharyya GS, Basu S, Agarwal V, Aaa A. Single institute phase II study of weekly cisplatinum and metronomic dosing of Endoxan and methotrexate in second line metastatic breast cancer triplenegative. Eur J Cancer 2009; 7:41; http://dx.doi.org/10.1016/S1359-6349(09)72076-2
   Google Scholar
• ClinicalTrials.gov:Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Paclitaxel in Triple Negative Breast Cancer (TNBC);
   Google Scholar
• Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin:mechanism of action and antineoplastic activity. Semin Oncol 1998; 25:4-12; PMID:9609103
   PubMed Web of Science ®Google Scholar
• Delpeuch A, Leveque D, Rob L, Bergerat JP. Off-label use of oxaliplatin in patients with metastatic breast cancer. Anticancer Res 2011; 31:1765-67; PMID:21617237
   PubMed Web of Science ®Google Scholar
• Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T. Oxaliplatin, tetraplatin, cisplatin, and carboplatin:spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 1996; 52:1855-65; PMID:8951344; http://dx.doi.org/10.1016/S0006-2952(97)81490-6
   PubMed Web of Science ®Google Scholar
• Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin:a review of preclinical and clinical studies. Ann Oncol 1998; 9:1053-71; PMID:9834817; http://dx.doi.org/10.1023/A: 1008213732429
   PubMed Web of Science ®Google Scholar
• Martin M, Ruiz A, Munoz M, Balil A, Garcia-Mata J, Calvo L, Carrasco E, Mahillo E, Casado A, Garcia-Saenz JA, et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes:final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 2007; 8:219-25; PMID:17329192; http://dx.doi.org/10.1016/S1470-2045(07)70041-4
   PubMed Web of Science ®Google Scholar
• Fumoleau P, Delgado FM, Delozier T, Monnier A, Gil DM, Kerbrat P, Garcia-Giralt E, Keiling R, Namer M, Closon MT, et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993; 11:1245-52; PMID:8315421
   PubMed Web of Science ®Google Scholar
• Garcia-Conde J, Lluch A, Martin M, Casado A, Gervasio H, De Oliveira C, De Pablo JL, Gorostiaga J, Giron GC, Cervantes A, et al. Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol 1994; 5:854-57; PMID:7848890
   PubMed Web of Science ®Google Scholar
• Petit T, Benider A, Yovine A, Bougnoux P, Spaeth D, Maindrault-Goebel F, Serin D, Tigaud JD, Eymard JC, Simon H, et al. Phase II study of an oxaliplatin/vinorelbine combination in patients with anthracycline- and taxane-pre-treated metastatic breast cancer. Anticancer Drugs 2006; 17:337-43; PMID:16520663; http://dx.doi.org/10.1097/00001813-200603000-00013
   PubMed Web of Science ®Google Scholar
• Monnet I, Soulie P, de Cremoux H, Saltiel-Voisin S, Bekradda M, Saltiel JC, Brain E, Dupont-Andre G, Cvitkovic E. Phase I/II study of escalating doses of vinorelbine in combination with oxaliplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2001; 19:458-63; PMID:11208839
   PubMed Web of Science ®Google Scholar
• Monnet I, de CH, Soulie P, Saltiel-Voisin S, Bekradda M, Saltiel JC, Brain E, Rixe O, Yataghene Y, Misset JL, et al. Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer:final results of a multicenter phase II study. Ann Oncol 2002; 13:103-07; PMID:11863089; http://dx.doi.org/10.1093/annonc/mdf006
   PubMed Web of Science ®Google Scholar
• Mir O, Alexandre J, Ropert S, Montheil V, Martin I, Durand JP, Goldwasser F. Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin:a single-center experience. Anticancer Drugs 2009; 20:105-08; PMID:19209026; http://dx.doi.org/10.1097/CAD.0b013e32831cdb51
   PubMed Web of Science ®Google Scholar
• Fennell DA, C SJ, Shamash J, Sheaff MT, Evans MT, Goonewardene TI, Nystrom ML, Gower NH, Rudd RM. Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma. Lung Cancer-J Iaslc 2005; 47:277-81; http://dx.doi.org/10.1016/j.lungcan.2004.08.005
   PubMed Web of Science ®Google Scholar
• Guerrero A, Servitja S, Rodriguez-Lescure A, Calvo L, Del BS, Quintanar MT, Juarez JI, Gayo J, Llombart A, Tusquets I. Phase I/II study of biweekly vinorelbine and oxaliplatin as first-line treatment in patients with metastatic breast cancer. Anticancer Drugs 2011; 22:283-89; PMID:21150776; http://dx.doi.org/10.1097/CAD.0b013e3283425c55
   PubMed Web of Science ®Google Scholar
• Baselga J, Gomez P, Greil R, Braga S, Climent MA, Wardley AM, Kaufman B, Stemmer SM, Pego A, Chan A, et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol 2013; 31:2586-92; PMID:23733761; http://dx.doi.org/10.1200/JCO.2012.46.2408
   PubMed Web of Science ®Google Scholar
• Hills CA, Kelland LR, Abel G, Siracky J, Wilson AP, Harrap KR. Biological properties of ten human ovarian carcinoma cell lines:calibration in vitro against four platinum complexes. Br J Cancer 1989; 59:527-34; PMID:2653399; http://dx.doi.org/10.1038/bjc.1989.108
   PubMed Web of Science ®Google Scholar
• Perez RP, O’Dwyer PJ, Handel LM, Ozols RF, Hamilton TC. Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines. Int J Cancer 1991; 48:265-69; PMID:2019469; http://dx.doi.org/10.1002/ijc.2910480219
   PubMed Web of Science ®Google Scholar
• Zelek L, Cottu P, Tubiana-Hulin M, Vannetzel JM, Chollet P, Misset JL, Chouaki N, Marty M, Gamelin E, Culine S, et al. Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients. J Clin Oncol 2002; 20:2551-58; PMID:12011135; http://dx.doi.org/10.1200/JCO.2002.06.164
   PubMed Web of Science ®Google Scholar
• Vassilomanolakis M, Koumakis G, Demiri M, Missitzis J, Barbounis V, Efremidis AP. Vinorelbine and cisplatin for metastatic breast cancer:a salvage regimen in patients progressing after docetaxel and anthracycline treatment. Cancer Invest 2003; 21:497-504; PMID:14533438; http://dx.doi.org/10.1081/CNV-120022358
   PubMed Web of Science ®Google Scholar
• Girre V, Dalenc F, Laurence V, Jouve M, Dieras V, Pierga J, Et A. Vinorelbine-5-fluorouracil combination as second line chemotherapy in metastatic breast cancer (MBC) after anthracyclinetaxanes combination (AT). Ann Oncol 2000; 11(Suppl 4):24.
   Google Scholar
• Delaloge S, Tubiana-Hulin M, Wardley A, Mastro LD, Santoro A, Zambelli A, Bonetti A, Boni C, Habib F, Brienza S. A multistep randomized phase II/III trial comparing oxaliplatin (OXA)+5 fluorouracil (FU) to vinorelbine (VIN)+FU (FUN) after taxane (T)/anthracycline (A) failure in advanced/metastatic breast cancer (MBC) patients (pts):Final results. Proc Am Soc Clin Oncol 2004; 22:660.
   Google Scholar
• Brufsky A, Valero V, Tiangco B, Dakhil S, Brize A, Rugo HS, Rivera R, Duenne A, Bousfoul N, Yardley DA. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer:subgroup analysis of the RIBBON-2 trial. Breast Cancer Res Treat 2012; 133:1067-75; PMID:22415477; http://dx.doi.org/10.1007/s10549-012-2008-6
   PubMed Web of Science ®Google Scholar
• Ma CX, Ellis MJ, Petroni GR, Guo Z, Cai SR, Ryan CE, Craig LA, Naughton MJ, Pluard TJ, Brenin CM, et al. A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. Breast Cancer Res Treat 2013; 137:483-92; PMID:23242585; http://dx.doi.org/10.1007/s10549-012-2378-9
   PubMed Web of Science ®Google Scholar